A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Tianjin Medical University Cancer Institute and Hospital
Seagen Inc.
Peking University
Bold Therapeutics, Inc.
Sun Yat-sen University
TransThera Sciences (Nanjing), Inc.
AIO-Studien-gGmbH
Jazz Pharmaceuticals
Merck Sharp & Dohme LLC
Toray Industries, Inc
First Affiliated Hospital of Zhejiang University
Lisata Therapeutics, Inc.
West China Hospital